Cell cycle proteins as promising targets in cancer therapy
T Otto, P Sicinski - Nature Reviews Cancer, 2017 - nature.com
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …
Vimentin and cytokeratin: Good alone, bad together
The cytoskeleton plays an integral role in maintaining the integrity of epithelial cells.
Epithelial cells primarily employ cytokeratin in their cytoskeleton, whereas mesenchymal …
Epithelial cells primarily employ cytokeratin in their cytoskeleton, whereas mesenchymal …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
[HTML][HTML] PLK1, a potential target for cancer therapy
Z Liu, Q Sun, X Wang - Translational oncology, 2017 - Elsevier
Abstract Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …
Plk1 inhibitors in cancer therapy: from laboratory to clinics
Abstract Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range
of tumors, prompting research and development of Plk1 inhibitors as a means of cancer …
of tumors, prompting research and development of Plk1 inhibitors as a means of cancer …
Present and future perspective on PLK1 inhibition in cancer treatment
Polo-like kinase 1 (PLK1) is the principle member of the well conserved serine/threonine
kinase family. PLK1 has a key role in the progression of mitosis and recent evidence …
kinase family. PLK1 has a key role in the progression of mitosis and recent evidence …
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is
associated with dismal outcomes. RAS pathway mutations, mainly NRAS G12D, define the …
associated with dismal outcomes. RAS pathway mutations, mainly NRAS G12D, define the …
Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies
Simple Summary Rhabdomyosarcoma (RMS) is a rare pediatric sarcoma affecting skeletal
muscle in children and young adults. It is responsible for 3% of all childhood malignant …
muscle in children and young adults. It is responsible for 3% of all childhood malignant …
A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
Acute myeloid leukemia (AML) is an extremely heterogeneous disease defined by the clonal
growth of myeloblasts/promyelocytes not only in the bone marrow but also in peripheral …
growth of myeloblasts/promyelocytes not only in the bone marrow but also in peripheral …
Recent advances and new strategies in targeting Plk1 for anticancer therapy
Polo-like kinase 1 (Plk1) plays key roles in regulating mitotic processes that are crucial for
cellular proliferation. Overexpression of Plk1 is tightly associated with the development of …
cellular proliferation. Overexpression of Plk1 is tightly associated with the development of …